Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study.

"Competing interests The authors declare no competing interests."

"Funding The study was financially supported by a grant from the Czech Health Research Council (NU20-07-00322) and Charles University (UNCE/MED/015), by the project 1000 braves (Foundation Nation for Children), by the “Kapka nadeje” foundation and by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic). Institutional support was provided by the project National Institute for Cancer Research (Project No. LX22NPO5102), funded by the European Union–Next Generation EU."

"The majority of children (n = 106) were treated according to the AML-BFM 2012 Registry protocol (Supplementary Fig. ), 14 children with Down syndrome and AML M7 (DS-AMKL) according to the ML-DS 2006 trial protocol (EudraCT trial #2007-006219-2), 10 children with acute prolymphocytic leukemia (APL) according to the amended AML-BFM 2012 Registry protocol, 2 children with APL according to the ICC APL study 02 protocol (NCT04793919) and one child with FLT3-ITD-positive NPM1-mutated AML was enrolled into CPKC412A2218 trial (NCT03591510). MRD monitoring was not used for risk stratification, but MRD monitoring for research purposes was performed in bone marrow (BM) at time-points defined by treatment protocols and when indicated by the physicians. Peripheral blood (PB) was occasionally analyzed in parallel with BM. In some patients, MRD monitoring continued after treatment either in BM (after hematopoietic stem cell transplantation, HSCT) or in PB. Biological samples were processed and nucleic acids were isolated according to standard laboratory procedures. Diagnostic and treatment procedures, protocols and the research study were approved by the Ethics Committee of University Hospital Motol (NU20-07-00322) and conducted in accordance with the Declaration of Helsinki. Written informed consent was provided by patients or their legal guardians."